NOVNHealthcare
Novartis AG
OverweightEarnings compounding has more room than current expectations imply.
Catalyst: Margin bridge · EVIDENCE CURRENTCONVICTIONHighOPEN NOTE
RESEARCH LIBRARY / 41 ACTIVE COVERAGE NOTES
Turn every observation into an evidence trail.
Centralised internal research connects thesis, valuation, catalysts, risks, and the portfolio decision they inform.
IMPLICATIONFour notes need review
CAPITAL COVERAGE91% research current
SOURCE STATEEvidence linked
OWNERResearch team
NEXT ACTIONRefresh valuation cases
ACTIVE COVERAGE
Research that carries portfolio weight.
Sorted by decision relevance and evidence freshness.
TCEHYCommunication
Tencent Holdings
OverweightMargin durability and capital allocation support the re-rating case.
Catalyst: Results transcript · EVIDENCE CURRENTCONVICTIONHighOPEN NOTE
ASMLTechnology
ASML Holding
NeutralStructural demand is intact; valuation buffer is narrower after the rally.
Risk: Order timing · EVIDENCE CURRENTCONVICTIONMediumOPEN NOTE
AIAFinancials
AIA Group
OverweightEmbedded value growth is improving as distribution productivity normalises.
Catalyst: China demand · EVIDENCE CURRENTCONVICTIONMediumOPEN NOTE
NVOHealthcare
Novo Nordisk
NeutralCategory leadership remains, but evidence needs to clear a higher valuation bar.
Risk: Supply dynamics · EVIDENCE CURRENTCONVICTIONMediumOPEN NOTE
THEMATIC NOTEBOOK
Cross-issuer ideas with a visible decision path.
AI capex: where the evidence is broadening.
Track earnings revision breadth across enabling infrastructure, not only the highest-beta beneficiaries.
China consumption: recovery path still uneven.
Use policy and transaction data as confirmation gates before increasing cyclical exposure.
Healthcare innovation: a selective risk budget.
Pair pipeline evidence with reimbursement and capacity constraints.